Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$84.950.00%
Close 2026-09-02 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · CRNX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -0.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 66 industry peers · Company calendar date is not available
CRNX — M&A activity — Changes in Control of Registrant
Dated 2026-09-01
Changes in Control of Registrant. The disclosures set forth in the Introductory Note and Items 2.01, 3.01, 3.03, 5.02 and 5.03 of this Current Report on Form 8-K are incorporated herein by reference. As a result of the consummation of the Merger, a change in control of the Company occurred and the Company became a wholly owned subsidiary of Parent. The aggregate consideration paid by Parent in connection with the Merger was approximately $10.0 billion, which was funded using a combination of…
Why it matters: The Cushing’s study could show if atumelnant has a role beyond CAH. Watch for trial progress and clear patient results.
Watch forVertex reports that the Phase 1/2b Cushing’s trial is enrolling and shares data showing a drop in disease markers.
Also watch forVertex reports a pause, delay, or end to the trial, or data that fail to show a drop in disease markers.
Why it matters: The CAH trial tests whether atumelnant can lower disease markers. Vertex’s update can show if the study is on track and what results support its use.
Watch forVertex reports that the CALM-CAH Phase 3 trial is enrolling and shares data showing lower key CAH markers.
Also watch forVertex reports a pause, delay, or end to CALM-CAH, or data that fail to lower key CAH markers.
Why it matters: Paltusotine is also in Phase 3 testing for carcinoid syndrome. Results can show whether it may serve patients beyond acromegaly.
Watch forVertex reports Phase 3 results that meet the trial’s main goal in carcinoid syndrome.
Also watch forVertex reports that the trial misses its main goal, is stopped, or is delayed beyond the stated study timeline.
Why it matters: PALSONIFY revenue rose from $10.3 million in Q1 to $24.0 million in Q2. Vertex’s next sales update can show whether demand keeps growing.
Watch forVertex reports PALSONIFY sales above $24.0 million in a later quarter. Patient starts or prescriber counts also rise.
Also watch forVertex reports PALSONIFY sales of $24.0 million or less in a later quarter. Patient starts or prescriber counts also fall.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$48 on $10,000 · ±0.5% | How much price usually moves either way. |
| Bad day | $513 loss on $10,000 · 5.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,221 loss on $10,000 · 42.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.